Integra Lifesciences Holdings Corp (NASDAQ:IART) saw an uptick in trading volume on Monday . 1,782,697 shares traded hands during trading, an increase of 141% from the previous session’s volume of 740,039 shares.The stock last traded at $49.68 and had previously closed at $46.55.

Several brokerages have recently weighed in on IART. BidaskClub downgraded shares of Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research report on Friday, January 5th. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Tuesday, October 10th. UBS Group restated a “buy” rating and set a $57.00 price objective on shares of Integra Lifesciences in a research report on Tuesday, October 31st. Jefferies Group restated a “buy” rating and set a $56.00 price objective on shares of Integra Lifesciences in a research report on Sunday, October 29th. Finally, Wells Fargo & Co downgraded shares of Integra Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Sunday, October 29th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $52.70.

The company has a market capitalization of $3,850.00, a price-to-earnings ratio of 81.21, a P/E/G ratio of 1.55 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 earnings per share. equities analysts forecast that Integra Lifesciences Holdings Corp will post 1.85 EPS for the current fiscal year.

In other news, VP Richard D. Gorelick sold 1,500 shares of Integra Lifesciences stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara B. Hill bought 10,768 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was acquired at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the acquisition, the director now directly owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. Insiders own 21.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP increased its holdings in shares of Integra Lifesciences by 213.1% in the 3rd quarter. GSA Capital Partners LLP now owns 28,249 shares of the life sciences company’s stock valued at $1,426,000 after acquiring an additional 19,226 shares during the period. California Public Employees Retirement System increased its stake in Integra Lifesciences by 6.8% in the 3rd quarter. California Public Employees Retirement System now owns 132,002 shares of the life sciences company’s stock valued at $6,663,000 after buying an additional 8,402 shares during the period. Zions Bancorporation acquired a new position in Integra Lifesciences in the 3rd quarter valued at $205,000. Orbimed Advisors LLC increased its stake in Integra Lifesciences by 155.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after buying an additional 664,000 shares during the period. Finally, Segall Bryant & Hamill LLC increased its stake in Integra Lifesciences by 20.9% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 112,520 shares of the life sciences company’s stock valued at $5,680,000 after buying an additional 19,486 shares during the period. 87.58% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/10/integra-lifesciences-iart-sees-large-volume-increase.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Receive News & Stock Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related stocks with our FREE daily email newsletter.